
    
      -  double-blind, non-inferiority, prospective, parallel group trial.

        -  Experiment duration: 05 days.

        -  03 visits (day 0, 48 hours and day 5).

        -  Efficacy will be evaluated for acute cutaneous rash based on symptoms score

        -  Adverse events evaluation.
    
  